Mohsen M A Abdelhafez, Karim A M Ahmed, Nashwa A M Ahmed, Mohd H Ismail, Mohd N M Daud, Aya M E Eldiasty, Mohd F B Amri, Mohammad S Jeffree, Fairrul K Masnah, Dg M P Baharuddin, Mohd F Bolong, Mohd F Hayati, Nornazirah B Azizan, Doreen Sumpat, Syed S S Abdul Rahim, Win W Than, Mohd Y Ibrahim, Zhen Z Lo, May Z Soe
Menopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence...
March 31, 2024: African Journal of Reproductive Health